Novartis blockbuster drug hit by scandal in Japan

|About: Novartis AG (NVS)|By:, SA News Editor

Researchers in Japan have retracted studies that promoted the benefits of one of Novartis' (NVS) biggest sellers in the country, the heart medicine Diovan.

The withdrawals came after university led investigations found data had been tampered with to create false results.

At least eight hospitals have said they'll stop prescribing the drug.

However, the impact in the U.S. is seen as limited, partly because Diovan is well established to the point that it's patent has expired. The drug's Japanese IP protection is due to end in later this year.